利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

48 条记录 (耗时 0.021 秒)

    ANTI-SCLEROSTIN ANTIBODIES AND THEIR USE TO TREAT BONE DISORDERS AS PART OF A REGIMEN
    6.
    发明申请
    ANTI-SCLEROSTIN ANTIBODIES AND THEIR USE TO TREAT BONE DISORDERS AS PART OF A REGIMEN 审中-公开
    抗沙门氏菌抗体及其用作治疗骨质疏松症的一部分

    公开(公告)号：WO2016092101A1

    公开(公告)日：2016-06-16

    申请号：PCT/EP2015/079496

    申请日：2015-12-11

    申请人： AMGEN INC. ,  UCB PHARMA S.A.

    发明人： ROBINSON, Martyn Kim ,  OMINSKY, Michael Stuart ,  LI, Xiaodong ,  KE, Hua Zhu

    IPC分类号： C07K16/22 ,  A61K39/00

    CPC分类号： C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61P19/08 ,  A61P19/10 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

    摘要： The invention relates to the treatment of bone disorders. In particular, the invention provides an approach involving administration of a high initial dose or doses of an sclerostin antibody to bring about a rapid increase in bone formation, followed by administration of lowers doses of the antibody to give a sustained lower rate of bone formation after the initial burst of bone formation. The invention also provides an approach involving decreasing dosing frequency with such an antibody to control bone formation. The approaches may be used in particular in those subjects who would benefit most from such an initial rapid burst of bone formation. Examples of such subjects include subjects who have been recently diagnosed or are experiencing severe symptoms of the disorder, as well as those subjects who have been administered a different treatment for the bone disorder which is proving ineffective. The approaches may be used in combination with each other.

    摘要翻译： 本发明涉及骨病的治疗。 特别地，本发明提供了一种方法，其包括施用高初始剂量或剂量的硬化蛋白抗体以引起骨形成的快速增加，随后施用较低剂量的抗体，以在持续较低的骨形成速率之后产生持续较低的骨形成速率 最初的骨骼形成爆发。 本发明还提供了一种涉及用这种抗体降低给药频率以控制骨形成的方法。 这些方法可以特别用于从这种初始的骨形成快速爆发中受益最大的受试者。 这些受试者的实例包括最近被诊断或正在经历该病症的严重症状的受试者，以及被证明无效的骨病症的不同治疗对象。 这些方法可以彼此组合使用。

    H3K27 DEMETHYLASE INHIBITORS IN PEDIATRIC AND JUVENILE OSTEOPOROSIS
    7.
    发明申请
    H3K27 DEMETHYLASE INHIBITORS IN PEDIATRIC AND JUVENILE OSTEOPOROSIS 审中-公开

    公开(公告)号：WO2019046378A1

    公开(公告)日：2019-03-07

    申请号：PCT/US2018/048465

    申请日：2018-08-29

    申请人： THE JOHNS HOPKINS UNIVERSITY

    发明人： WAN, Mei ,  CAO, Xu

    IPC分类号： A61K31/55 ,  A61P19/10

    CPC分类号： A61P19/10 ,  A61K31/55 ,  A61K31/573 ,  A61K2300/00

    摘要： The present invention provides methods for manipulating epigenetic factors to treat pediatric or juvenile osteoporosis. Specifically, the present invention provides methods for the application of H3K27 demethylase inhibitors in pediatric or juvenile subjects with osteoporosis. Thus, the present invention provides methods of administration of the H3K27 demethylase inhibitor, GSK-J4, to pediatric or juvenile subjects to effectively inhibit primary and secondary pediatric osteoporosis, especially for long-term glucocorticoid treated patients (juvenile rheumatoid disorders, Crohn's disease, nephrotic syndrome, and Duchenne muscular dystrophy) and patients who have compromised mobility (cerebral palsy, Rett syndrome, Duchenne muscular dystrophy, spina bifida, and spinal muscular atrophy).

    USES OF SATL-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS
    10.
    发明申请
    USES OF SATL-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS 审中-公开
    SATL诱导激酶（SIK）抑制剂在治疗骨质疏松症中的应用

    公开(公告)号：WO2018053373A1

    公开(公告)日：2018-03-22

    申请号：PCT/US2017/051937

    申请日：2017-09-16

    申请人： THE GENERAL HOSPITAL CORPORATION ,  THE BROAD INSTITUTE, INC.

    发明人： WEIN, Marc ,  KRONENBERG, Henry ,  SUNDBERG, Thomas ,  XAVIER, Ramnik

    IPC分类号： A61K31/5377 ,  A61K31/519 ,  A61P19/10

    CPC分类号： A61P19/10 ,  A61K31/519 ,  A61K31/5377

    摘要： The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).

    摘要翻译： 本公开提供了使用盐诱导型激酶（SIK）抑制剂治疗和/或预防骨质疏松症的方法。 还提供了使用SIK抑制剂增加骨细胞功能，增加成骨细胞数量，增加成骨细胞活性，抑制骨吸收，减少破骨细胞数量，抑制破骨细胞活性，增加 骨，下调基因SOST的表达，和/或抑制硬骨素的活性。 SIK抑制剂可以与Src抑制剂或CSF1R抑制剂组合。 示例性的SIK抑制剂包括式（I），（II），（III），（IV），（V）或（VI）的化合物。